Medical Device

Pr VYZULTA ® Added Under Alberta, Saskatchewan Manitoba New Brunswick Nova Scotia Newfoundland and Labrador and Federal Non-Insured Health Benefits Plans  Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. announced that Pr VYZULTA ® which is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension i now has expanded public ...
  • Pr VYZULTA ® Added Under Alberta, Saskatchewan , Manitoba , New Brunswick , Nova Scotia , Newfoundland and Labrador , and Federal Non-Insured Health Benefits (NIHB) Plans

 Bausch + Lomb., a leading global eye health business of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), announced that Pr VYZULTA ® (latanoprostene bunod ophthalmic solution, 0.024% ww), which is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension i now has expanded public drug program reimbursement in the provinces of Alberta Saskatchewan Manitoba New Brunswick Nova Scotia Newfoundland and Labrador and as part of the federal Non-Insured Health Benefits (NIHB).

These provinces join Ontario , which made VYZULTA available to patients in December 2019 . ii

Affecting over 400,000 Canadians, glaucoma is a disease of the optic nerve and the leading cause of blindness in North America . iii

"We are pleased that a growing number of provinces and the federal government recognize the impact of glaucoma on patients and the health care system and are increasing access to VYZULTA, a new option that can help patients manage this potentially life-altering condition and possibly preserve eyesight," said Richard Lajoie, President and General Manager of Bausch Health, Canada. "Bausch + Lomb is very proud of the part we play in helping Canadians live better by enabling them to see better with our products."

VYZULTA has a dual mechanism of action for lowering intraocular pressure by increasing outflow of aqueous humor through both uveoscleral and trabecular meshwork routes. i VYZULTA is to be administered once daily.

"VYZULTA is the first molecule introduced into Canada in approximately 20 years with a unique mode of action for reducing eye pressure, and is an important advancement in the medical management of glaucoma because it offers a novel therapeutic option for our patients," said Dr. David Yan , Ophthalmologist-in-Chief, Sinai Health System.

For Canadians, glaucoma is one of the leading causes of irreversible blindness. iv Glaucoma is defined as a group of eye diseases that slowly and progressively affect the optic nerve, v which can lead to irreversible vision loss. Open-angle glaucoma is the most common form of the disease and is associated with elevated pressure caused by a backup of fluid in the eye. vi

"The governments of Alberta , Saskatchewan , Manitoba , Ontario , New Brunswick , Nova Scotia , Newfoundland and Labrador , and the federal government, through the Non-Insured Health Benefits program are showing their commitment to advancing the standard of care for glaucoma patients by making Vyzulta available to patients on public formularies," said Doug Earle, President & CEO, Fighting Blindness Canada. "On behalf of the constituents of Fighting Blindness Canada, I am heartened to see that people in these provinces and jurisdictions living with open-angle glaucoma now have access to another treatment option that they can discuss with their optometrist or ophthalmologist."

VYZULTA received its Notice of Compliance (NOC) from Health Canada on Dec. 27, 2018 and is currently covered by most private insurance plans in Canada.

About Bausch + Lomb
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in approximately 100 countries. For more information, visit www.bausch.ca .

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC ) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

In Canada, our areas of focus include eye health, dermatology and cardio metabolic. More information can be found at www.bauschhealth.ca .

______________________________

i

Pr Vyzulta ® Product Monograph, dated December 27, 2018.

ii

Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Summary of Changes – December 2019 Effective December 20, 2019,p.5; http://www.health.gov.on.ca/en/pro/programs/drugs/formulary43/summary_edition43_20191213.pdf

iii

CADTH Common Drug Review - Patient Input. Latanorpostene Bunod (Vyzulta). December 12, 2018. https://www.cadth.ca/sites/default/files/cdr/relatedinfo/SR0590%20Vyzulta%20-%20Patient%20Group%20Input_January%208%2C%202019.pdf Accessed: September 18, 2020

iv

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. British Journal of Ophthalmology. 2006;90(3):262 v Horton JC. Disorders of the Eye. In: Kasper D, Fauci A, Hauser S, Longo D, Jameson JL, Loscalzo J, eds. Harrison's Principles of Internal Medicine, 19e . New York, NY: McGraw-Hill Education; 2015.

vi

Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee; Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol. 2009;44 Suppl 1:S7-S93.

SOURCE Bausch + Lomb Canada

News Provided by Canada Newswire via QuoteMedia

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion .

"We are very excited to officially welcome our PPD colleagues to Thermo Fisher Scientific," said Marc N. Casper , chairman, president and chief executive officer of Thermo Fisher Scientific. "Expanding our value proposition for our biotech and pharmaceutical customers with the addition of PPD's leading clinical research services advances our work in bringing life-changing therapies to market, benefitting patients around the world."

Keep reading... Show less
UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

UPDATED - Leveljump Healthcare Corp. Announces 14.6% Minority Investment in Real Time Medical Approved by TSXV and Closed

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce that, it has received TSXV approval, and has closed its acquisition of a 14.6% minority equity interest in Real Time Medical Inc. ("RTM"), a private Ontario company, in exchange for 2,494,576 units (a "Unit") of Leveljump. Each Unit will be issued at a price of $0.66 per Unit with each Unit being comprised of three (3) Leveljump common shares at a deemed price of $0.22 per share and one (1) share purchase warrant of Leveljump, each warrant entitling the holder to acquire one additional common share of Leveljump at a price of $0.35 per common share on or before December 31, 2023.

The equity interest in RTM was acquired through a mini-tender offer to the shareholders of RTM dated November 1, 2021 whereby JUMP offered to acquire up to 19.9% of RTM in exchange for the Units. The holders of the RTM shares who have tendered are all accredited investors.

Keep reading... Show less
Leveljump Healthcare Strengthens Board of Directors

Leveljump Healthcare Strengthens Board of Directors

LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("Leveljump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce new additions to its board of directors and its advisory board.

Gary Prihar - Director

Keep reading... Show less
ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies and Infinovo Sign Memorandum of Understanding to Manufacture World's First CGM for Diabetic Pets

ALR Technologies ("ALRT" or the "Company") (OTCQB: ALRT), the diabetes management company, is pleased to announce the signing of a Memorandum of Understanding ("MOU") with Infinovo Medical Co. Ltd for a global supply agreement of their P3 Continuous Glucose Monitor (CGM) for use by ALRT in the animal health sector.

Under the terms of the MOU, ALR Technologies and Infinovo will collaborate to integrate Infinovo's P3 CGM with ALRT's proprietary GluCurve platform. The Company expects to begin testing the GluCurve Pet CGM in veterinary clinics in late December 2021 or early January 2022. The testing is scheduled to complete by the end of February 2022.

Keep reading... Show less

Medtronic Hugo robotic-assisted surgery system receives Health Canada licence, further enabling access to robotic-assisted surgery in Canada

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT), the world's leading medical technology company, announced it has received a Health Canada licence for the Hugo™ robotic-assisted surgery (RAS) system for use in use in urologic and gynecologic laparoscopic surgical procedures, which make up about half of all robotic procedures performed today. 1

Keep reading... Show less

APMA Grants Seal of Approval for JUBLIA® Topical Solution, 10%

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced JUBLIA ® (efinaconazole) Topical Solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, has received the American Podiatric Medical Association (APMA) Seal of Approval. The APMA Seal of Approval is granted to products that promote good foot health and are of significant value when used in a consistently applied program of daily foot care and regular professional treatment.

Keep reading... Show less

Top News

Related News